Michael Burkes Brophy Sells 1,238 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,238 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $146,343.98. Following the sale, the chief financial officer now directly owns 71,471 shares in the company, valued at approximately $8,448,586.91. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total value of $82,097.71.
• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The shares were sold at an average price of $119.09, for a total value of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The shares were sold at an average price of $120.76, for a total value of $73,422.08.

Natera Stock Up 1.6 %

Shares of NASDAQ:NTRA traded up $1.99 during mid-day trading on Wednesday, hitting $126.73. 794,882 shares of the company traded hands, compared to its average volume of 1,316,621. The firm has a market cap of $15.67 billion, a P/E ratio of -51.71 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 52-week low of $37.67 and a 52-week high of $133.54. The firm’s 50 day simple moving average is $123.31 and its 200 day simple moving average is $111.82.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue was up 58.1% on a year-over-year basis. During the same period last year, the business posted ($0.97) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the topic of a number of analyst reports. Morgan Stanley increased their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Friday, October 25th. Leerink Partners raised their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. TD Cowen raised their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Canaccord Genuity Group raised their price target on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $125.69.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Vanguard Group Inc. grew its position in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after acquiring an additional 72,848 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after acquiring an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Natera by 6.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after acquiring an additional 148,917 shares in the last quarter. Duquesne Family Office LLC grew its position in shares of Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after acquiring an additional 45,500 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after acquiring an additional 246,246 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.